Japanese regulatory authority's perspective on biosimilars

Lancet Oncol. 2015 Mar;16(3):e101. doi: 10.1016/S1470-2045(14)71220-3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Biosimilar Pharmaceuticals / standards*
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Drug Approval / legislation & jurisprudence*
  • Humans
  • Neoplasms / drug therapy*

Substances

  • Antineoplastic Agents
  • Biosimilar Pharmaceuticals